Cancer is the second leading cause of death worldwide. Cervical cancer, for instance, is considered a major scourge in low-income countries. Its development is mostly associated with the human papillomavirus persistent infection and despite the availability of preventive vaccines, they are only widely administered in more developed countries, thus leaving a large percentage of unvaccinated women highly susceptible to this type of cancer. Current treatments are based on invasive techniques, being far from effective. Therefore, the search for novel, advanced and personalized therapeutic approaches is imperative. Flavonoids belong to a group of natural polyphenolic compounds, well recognized for their great anticancer capacity, thus promising to be incorporated in cancer therapy protocols. However, their use is limited due to their low solubility, stability and bioavailability. To surpass these limitations, the encapsulation of flavonoids into delivery systems emerged as a valuable strategy to improve their stability and bioavailability. In this context, the aim of this review is to present the most reliable flavonoids-based delivery systems developed for anticancer therapies and the progress accomplished, with a special focus on cervical cancer therapy. The gathered information revealed the high therapeutic potential of flavonoids and highlights the relevance of delivery systems application, allowing a better understanding for future studies on effective cancer therapy.
Quercetin is a natural flavonoid with high anticancer activity, especially for related-HPV cancers such as cervical cancer. However, quercetin exhibits a reduced aqueous solubility and stability, resulting in a low bioavailability that limits its therapeutic use. In this study, chitosan/sulfonyl-ether-β-cyclodextrin (SBE-β-CD)-conjugated delivery systems have been explored in order to increase quercetin loading capacity, carriage, solubility and consequently bioavailability in cervical cancer cells. SBE-β-CD/quercetin inclusion complexes were tested as well as chitosan/SBE-β-CD/quercetin-conjugated delivery systems, using two types of chitosan differing in molecular weight. Regarding characterization studies, HMW chitosan/SBE-β-CD/quercetin formulations have demonstrated the best results, which are obtaining nanoparticle sizes of 272.07 ± 2.87 nm, a polydispersity index (PdI) of 0.287 ± 0.011, a zeta potential of +38.0 ± 1.34 mV and an encapsulation efficiency of approximately 99.9%. In vitro release studies were also performed for 5 kDa chitosan formulations, indicating a quercetin release of 9.6% and 57.53% at pH 7.4 and 5.8, respectively. IC50 values on HeLa cells indicated an increased cytotoxic effect with HMW chitosan/SBE-β-CD/quercetin delivery systems (43.55 μM), suggesting a remarkable improvement of quercetin bioavailability.
To reach the target tissue within the central nervous system (CNS), drugs, such as donepezil (DNPZ), must overcome naturally occurring barriers. Despite its substantial pharmacological relevance, the blood–cerebrospinal fluid barrier (BCSFB) remains insufficiently studied. The BCSFB harbors a functional molecular clock that regulates, for instance, the expression of membrane transporters. Thus, there has been an increasing interest in exploring chronotherapeutic strategies to enhance cerebral drug delivery. Additionally, nanotechnology constitutes a well-established approach for improving tissue-specific drug bioavailability within the CNS through, for example, the employment of chitosan (CS)-based nanosystems. Given the considerable potential of both approaches for the treatment of neurological disorders, we propose establishing an integrated chronotherapy–nanotechnology platform to optimize pharmacological regimens. In this context, this study aims to explore the influence of circadian rhythms in the transport of free and encapsulated DNPZ forms across an in vitro model of the BCSFB. We developed and characterized CS-based nanoparticles with promising properties for the enhanced delivery of DNPZ across brain barriers. We found that free and encapsulated drug forms of DNPZ display distinct patterns of circadian trafficking across BCSFB. In summary, our findings represent an important step toward the integration of chronotherapy and nanotechnology as a promising strategy to optimize therapeutic outcomes.